Orexin–Corticotropin-Releasing Factor Receptor Heteromers in the Ventral Tegmental Area as Targets for Cocaine

Gemma Navarro,1,* César Quiroz,2,* David Moreno-Delgado,1 Adam Sierakowiak,2 Kimberly McDowell,3 Estefanía Moreno,1 William Rea,2 Ning-Sheng Cai,1 David Aguinaga,1 Lesley A. Howell,1 Felix Hausch,1 Antonio Cortés,1 Josefà Mallol,1 Vicent Casadó,1 Carme Lluís,1 Enric I. Canela,1† Sergi Ferré,2† and Peter J. McCormick1,3†

1Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Center for Biomedical Research in Neurodegenerative Diseases Network and Institute of Biomedicine of the University of Barcelona, 08028 Barcelona, Spain, 2Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224, 3School of Pharmacy, University of East Anglia, Norwich, NR4 7TJ, United Kingdom, and 4Max Planck Institute of Psychiatry, 80804 Munich, Germany

Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegmental area (VTA) play an important role in stress-induced cocaine-seeking behavior. We provide evidence for pharmacologically significant interactions between CRF and orexin-A that depend on oligomerization of CRF receptor (CRF1R) and orexin OX1 receptors (OX1R). CRF1R–OX1R heteromers are the conduits of a negative crosstalk between orexin-A and CRF as demonstrated in transfected cells and rat VTA, in which they significantly modulate dendritic dopamine release. The cocaine target σ1 receptor (σ1R) also associates with the CRF1R–OX1R heteromer. Cocaine binding to the σ1R–CRF1R–OX1R complex promotes a long-term disruption of the orexin-A–CRF negative crosstalk. Through this mechanism, cocaine sensitizes VTA cells to the excitatory effects of both CRF and orexin-A, thus providing a mechanism by which stress induces cocaine seeking.

Key words: cocaine; CRF receptor; GPCR heteromer; orexin receptor; sigma receptor

Introduction

The 41 aa neuropeptide corticotropin-releasing factor (CRF) plays an important role in stress-induced drug-seeking behavior (Sarnyai et al., 2001). This depends primarily on CRF release in the ventral tegmental area (VTA), which receives CRF inputs from the paraventricular nucleus and the limbic forebrain (Rodaros et al., 2007). Stress and addictive drugs sensitize VTA dopaminergic neurons to the effects of excitatory inputs by common synaptic modifications (Saal et al., 2003), which can be reproduced by VTA application of CRF (Ungless et al., 2003). In the VTA of cocaine-experienced but not naive animals, stress-induced CRF release increases extracellular levels of glutamate and dopamine (Wang et al., 2005, 2007). Of the two known CRF receptors (CRF1R and CRF2R), CRF1R is involved preferentially from stress-induced reinstatement of cocaine-seeking behavior and VTA dopamine release (Shaham et al., 1998; Lu et al., 2003; Lodge and Grace, 2005; Blacktop et al., 2011).

The 33- and 28-aa-long neuropeptides orexin-A (hypocretin-A) and orexin-B (hypocretin-B) are expressed within cell bodies in the lateral hypothalamus and adjacent perifornical area (Sakurai et al., 1998; de Lecea et al., 1998). These cells are the origin of an ascending arousal system that projects to the entire cortex, but apart from their well established role in arousal, orexins have a role in reward processes and substance-use disorders, which might depend on the dense orexinergic innervation of the dopaminergic cells of the VTA (Borgland et al., 2010; Mahler et al., 2014; Sakurai, 2014). A dichotomy in orexin function appears to be related to the two identified orexin receptors, with reward and arousal being associated closely with activation of OX1R and OX2R, respectively (Borgland et al., 2010; Mahler et al., 2014). The orexin–hypocretin system also drives cocaine reinstatement through activation of stress pathways, which includes the participation of CRF. Thus, central administration of orexin-A led to a dose-related reinstatement of cocaine seeking, which was prevented by a nonselective CRF1R antagonist, and a selective OX1R antagonist.
antagonist blocked stress-induced reinnervation of previously extinguished cocaine-seeking behavior (Boutet et al., 2005).

The same as for CRF, VTA is a key brain area involved in the ability of the orexigenic system to promote cocaine seeking. Intra-VTA administration of orexin-A reinstated cocaine self-administration, which was also associated with VTA glutamate and dopamine release (Wang et al., 2009). Intriguingly, although CRF and orexin-A are involved in stress-induced cocaine reinnervation by acting in the VTA, their mechanisms appeared independent (Wang et al., 2009). In the present study, we provide evidence for the existence of pharmacologically significant interactions between CRF and orexin-A that depend on CRF-R–OX1R oligomerization. CRF–R–OX1R heteromers are the conduits of a negative crosstalk between orexin-A and CRF observed in transfected cells and the VTA, in which they can significantly influence dendritic dopamine release. We also demonstrate that CRF-R–OX1R heteromers associate with σ1 receptors (σ1Rs) to form CRF–R–OX1R–σ1R complexes and that cocaine binding to σ1R in the complex promotes a long-term disruption of the orexin-A–CRF negative crosstalk. Through this mechanism, cocaine sensitizes VTA cells to the excitatory effects of both CRF and orexin-A.

Materials and Methods

Ligands and HIV transactivator of transcription-linked peptides. (−)-Cocaine HCl was purchased from Sigma and from the Spanish Agency of Medicine (number 20030C0020). σ1 ligands PD144418 (1,2,3,6-tetrahydro-5-[3-(4-methylphenyl)-5-oxazolyl]-1-propylpyridine oxalate) and PRE-084 2,4-(4-morpholinyl) 1-phenyloxycarbonyloxytriglycyl-1,5-naphtalidin-4-yl urea, and NBZ27914 [5-chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride] were purchased from Tocris Bioscience. To allow intracellular delivery, a peptide or protein can be fused to the cell-penetrating HIV transactivator of transcription (TAT) peptide (YGRKKRRQRRR; Schwarze et al., 1999). HIV TAT fused to a peptide with the amino acid sequence of a transmembrane domain (TM) of a GPCR can be inserted effectively into the plasma membrane as a result of both the penetration capacity of the TAT domain (TM) of a GPCR can be inserted effectively into the plasma membrane and the hydrophobic property of the TM domain (He et al., 2011). HIV TAT-fused peptides with the amino acid sequences of OX1R TM domains TM1, TM5, and TM7 were used (Genemad Synthesis). To obtain the right orientation of the inserted peptide, HIV TAT peptide was fused to the C terminus of OX1R TM1, TM5, and TM7 peptides, with the following final amino acid sequences: WV-LA1AYAVFVFLALVGNTLYGRRRQRRRR, SCFFVFTYLAPLGLMGMAFQYFGYYRQRRRR, and YACFTFSHWLVYANLIAAYVAVFLIALVGNTLYGRRRQRRRR, respectively. Expression vectors, fusion proteins, and CRF R mutants. Sequences encoding amino acid residues 1-155 and 156-238 of yellow fluorescent protein (YFP) Venus protein were subcloned in pcDNA3.1 vector to obtain YFP Venus hemitranscribed proteins. Human cDNAs for OX1R, CRF-R, ghrelin 1a receptors [growth hormone secretagogue 1a receptor (GHS1aR)], or σ1R, cloned into pcDNA3.1, were amplified without their stop codons using sense and antisense primers harboring the following: EcoRI and KpnI sites to clone CRF-R, OX1R, or GHS1aR in pcDNA3.1Luc vector (pRLuc–N1; PerkinElmer Life and Analytical Sciences) or pEYFP–N1 vector (enhanced yellow variant of GFP; Clontech), HindIII and BamHII sites to clone σ1R in pEYFP–N1 vector, or EcoRI and BamHII sites to clone CRF-R, OX1R, and GHS1aR in Cherry containing vector (pcDNA3.1-Cherry). Amplified fragments were subcloned to in-frame with restriction sites of pRLuc–N1, pEYFP–N1, or pcDNA3.1-Cherry vectors to provide plasmids that express fusion proteins fused to Renilla Luciferase (RLuc), YFP, or Cherry on the C-terminal end (OX-R–RLuc, CRF–R–RLuc, OX-R–YFP, CRF–R–YFP, GHS1aR–GHS1aR, σ1R–R–σ1R, or CRF–R–Cherry). Dr. Marian Castro (University of Santiago de Compostela, Santiago de Compostela, Spain) generously provided human β-arrestin 2–RLuc6 cDNA, cloned in pcDNA3.1 RLuc6 vector (pRLuc–N1; PerkinElmer Life and Analytical Sciences). For bimolecular fluorescence complementation (BiFC) experiments, human cDNA for CRF–R, was also subcloned into pcDNA3.1–nVenus to provide a plasmid that expresses the receptor fused to the hemitransminated nYFP Venus on the C-terminal end of the receptor (CRFR1–nVenus), and human cDNA for OX1R was also subcloned into pcDNA3.1–cVenus to provide a plasmid that expresses the receptor fused to the hemitransminated cYFP Venus on the C-terminal end of the receptor (OX1R–cVenus). Two CRF-R mutants were used: (1) CRF-R433, which lacks a large portion of the extra-cellular domain of the N terminus (amino acids 1–111) and is not able to bind ligands (Devigny et al., 2011); and (2) CRF-R432, with H405P and A119L mutations in the 3 IL that confer enhanced constitutive activity.

Cell clones, cell culture, and transient transfection. HEK-293T cells were grown in DMEM (Gibco) supplemented with 2 mM l-glutamate, 100 µg/ml sodium pyruvate, 100 U/ml penicillin/streptomycin, minimal essential medium non-essential amino acids solution (1:100), and 5% (v/v) heat-inactivated fetal bovine serum (Invitrogen) and were maintained at 37°C in an atmosphere with 5% CO2. Cells were transiently transfected with the corresponding fusion protein cDNA by the polyethylenimine (Sigma) method. For receptor–heteromer signaling, 0.4 µg of OX1R–RLuc cDNA and 0.3 µg of CRF-R–YFP cDNA were transfected, which provides 80–90% of maximum bioluminescence resonance energy transfer (BRET), as deduced from the BRET saturation curves (Fig. 1), indicating a high degree of receptor heteromerization. For the expression of GHS1aR–YFP, equal amounts of GHS1aR–YFP and GHS1aR cDNA were transfected to ensure GHS1aR expression at the cell membrane. HEK-293T stable cell lines expressing CRF-R–YFP or OX1R–Venus fusion proteins were created by transfection of the corresponding cDNA in a pCDNA3.1 plasmid. Antibiotic-resistant clones were isolated with 1000 µg/ml geneticin (Invitrogen), and, after an appropriate number of passages, stable cell lines were selected and grown as above indicated in the presence of 500 µg/ml geneticin. Sample protein concentration was determined as a control of cell number using a Bradford assay kit (Bio-Rad) with bovine serum albumin (BSA) dilutions as standards.

Fluorescence complementation assays. HEK-293T cells were cotransfected with 0.6 µg CRF-R–nVenus cDNA and 0.6 µg OX1R–cVenus cDNA; 48 h after transfection, cells were treated or not with the indicated HIV TAT–TM fused peptides (4 µM) for 60 min at 37°C. To quantify protein–constituted YFP Venus expression, cells (20 µg of protein) were distributed in 96-well microplates (black plates with a transparent bottom; Porvair), and fluorescence was read in a Fluo Star Optima Fluorimeter (BMG Labtech) equipped with a high-energy xenon flash lamp, using a 10 nm bandwidth excitation filter at 400 nm reading. Protein fluorescence expression was determined as fluorescence of the sample minus the fluorescence of cells not expressing the fusion proteins.

Resonance energy transfer experiments. For BRET assays, HEK-293T cells were transiently cotransfected with a constant amount of cDNAs encoding proteins fused to Renilla and with increasing amounts of cDNAs corresponding to proteins fused to YFP. To quantify protein YFP expression, cells (20 µg of protein) were distributed in 96-well microplates (black plates with a transparent bottom), and fluorescence was read in the Fluo Star Optima Fluorimeter using a 10 nm bandwidth excitation filter at 400 nm reading. Protein fluorescence expression was determined as fluorescence of the sample minus the fluorescence of cells expressing the BRET donor alone. For BRET measurements, the equivalent of 20 µg of cell suspension were distributed in 96-well microplates (Corning 3600, white plates; Sigma), and coelenterazine H (5 µM; Invitrogen) was added. After 1 min, readings were obtained using a Mithras LB 940 (Berthold Technologies) that allows the integration of the signals detected in the short-wavelength filter at 485 nm and the long-wavelength filter at 530 nm. To quantify protein RLuc expression luminescence, readings were also performed 10 min after addition of coelenterazine H (5 µM). For sequential resonance energy transfer (SRET) assays, HEK-293T cells were transiently cotransfected with constant amounts of cDNAs encoding for both receptor fused to RLuc and YFP proteins and with increasing amounts of cDNA corresponding to the receptor fused to Cherry protein. After 48 h of transfection, quantification of YFP and RLuc proteins was performed in parallel in aliquots of transfected cells (20 µg of protein); (1) quantification of receptor YFP or receptor RLuc expression was performed as indicated for BRET experiments; (2) for quanti-
Navarro et al. • Orexin–CRF Receptor Heteromers in the VTA  
J. Neurosci., April 29, 2015 • 35(17):6639 – 6653 • 6641

**Figure 1.** CRF/R-OR heteromers in transfected HEK-293T cells. A, BRET saturation experiments in cells transfected with OX1R–RLuc cDNA (0.4 µg) and increasing amounts of CRF1R–YFP cDNA (0.05–0.5 µg). Low and linear BRET is observed in cells transfected with OX1R–RLuc cDNA (0.4 µg) and GHS1aR–YFP cDNA (0.4–2 µg). BRET, expressed as mBU, is given as a function of 1000 × ratio of fluorescence of the acceptor (YFP) and Luciferase activity of the donor (RLuc). Values are means ± SEMs of six to seven replications of one independent experiment per point. B, Confocal microscopy images (superimposed sections) from PLA experiments performed in HEK-293T cells transfected with CRF1R–YFP cDNA (0.3 µg) and OX1R–RLuc cDNA (0.4 µg) (left) or GHS1aR–YFP cDNA (2 µg) and OX1R–RLuc cDNA (0.4 µg) (right). Heteromeric complexes appear as red spots and cell nuclei in blue (DAPI stained). Scale bars, 20 µm. C, Confocal microscopy images of HEK-293T cells transfected with CRF1R–YFP cDNA (0.3 µg; left), OX1R–RLuc cDNA (0.4 µg; middle), or GHS1aR–YFP (2 µg; right). YFP-fused receptors are identified by their own fluorescence (green) and OX1R–RLuc by immunocytochemistry (red). Scale bars, 10 µm. D, ERK1/2 phosphorylation in HEK-293T cells transfected with CRF1R, CRF1R–RLuc, or CRF1R–YFP cDNA (0.3 µg; white columns) or with OX1R, OX1R–RLuc, or OX1R–YFP cDNA (0.4 µg; black columns) were treated with CRF (100 nM) or orexin-A (50 nM), respectively. Values are means ± SEMs of seven experiments per group and are expressed as percentage of basal levels (100%). One-way ANOVA followed by Bonferroni’s multiple comparison post hoc test shows significant agonist effect versus basal values (**p < 0.01 and ***p < 0.001). Representative Western blots are at the bottom.

**Figure 1.** CRF1R–OR heteromers in transfected HEK-293T cells. A, BRET saturation experiments in cells transfected with OX1R–RLuc cDNA (0.4 µg) and increasing amounts of CRF1R–YFP cDNA (0.05–0.5 µg). Low and linear BRET is observed in cells transfected with OX1R–RLuc cDNA (0.4 µg) and GHS1aR–YFP cDNA (0.4–2 µg). BRET, expressed as mBU, is given as a function of 1000 × ratio of fluorescence of the acceptor (YFP) and Luciferase activity of the donor (RLuc). Values are means ± SEMs of six to seven replications of one independent experiment per point. B, Confocal microscopy images (superimposed sections) from PLA experiments performed in HEK-293T cells transfected with CRF1R–YFP cDNA (0.3 µg) and OX1R–RLuc cDNA (0.4 µg) (left) or GHS1aR–YFP cDNA (2 µg) and OX1R–RLuc cDNA (0.4 µg) (right). Heteromeric complexes appear as red spots and cell nuclei in blue (DAPI stained). Scale bars, 20 µm. C, Confocal microscopy images of HEK-293T cells transfected with CRF1R–YFP cDNA (0.3 µg; left), OX1R–RLuc cDNA (0.4 µg; middle), or GHS1aR–YFP (2 µg; right). YFP-fused receptors are identified by their own fluorescence (green) and OX1R–RLuc by immunocytochemistry (red). Scale bars, 10 µm. D, ERK1/2 phosphorylation in HEK-293T cells transfected with CRF1R, CRF1R–RLuc, or CRF1R–YFP cDNA (0.3 µg; white columns) or with OX1R, OX1R–RLuc, or OX1R–YFP cDNA (0.4 µg; black columns) were treated with CRF (100 nM) or orexin-A (50 nM), respectively. Values are means ± SEMs of seven experiments per group and are expressed as percentage of basal levels (100%). One-way ANOVA followed by Bonferroni’s multiple comparison post hoc test shows significant agonist effect versus basal values (**p < 0.01 and ***p < 0.001). Representative Western blots are at the bottom.
animals were housed two per cage and kept on a 12 h light/dark cycle with food and water available ad libitum, and experiments were performed during the light cycle. All procedures were approved by the Catalan Ethical Committee for Animal Use (CEAA/DMAH 4049 and 5664). Animals were killed by decapitation under 4% isoflurane anesthesia, and brains were rapidly removed, placed in ice-cold oxygenated (O2/CO2, 95%/5%) Krebs–HCO3 buffer (in mM: 124 NaCl, 4 KCl, 1.25 KH2PO4, 1.5 MgCl2, 1.5 CaCl2, 10 glucose, and 26 NaHCO3, pH 7.4) and sliced at 4°C using a brain matrix (Zivic Instruments). VTA slices (500 μm thick) were kept at 4°C in Krebs–HCO3 buffer during the dissection; each slice was transferred into a 12-well plate with Corning Netwell inserts, containing 2 ml of ice-cold Krebs–HCO3 buffer. The temperature was raised to 23°C, and, after 30 min, the medium was replaced by 2 ml of fresh Krebs–HCO3 buffer (23°C). Slices were incubated under constant oxygenation (O2/CO2, 95%/5%) at 30°C for 4 h in an Eppendorf Thermostomix (5 Prime), and the medium was replaced by fresh Krebs–HCO3 buffer and incubated for 30 min before the addition of any agent. After incubation, the solution was discarded, and slices were frozen on dry ice and stored at −80°C until ERK1/2 phosphorylation was determined.

Akt and ERK1/2 phosphorylation. Cells or rat VTA slices were treated or not with the indicated ligands for the indicated time and were lysed by the addition of 300 μl of ice-cold lysis buffer (50 mM Tris–HCl, pH 7.4, 50 mM NaF, 150 mM NaCl, 45 mM β-glycerophosphate, 1% Triton X-100, 20 μM phenyl-arsine oxide, 0.4 mM NaVO4, and protease inhibitor mixture). Cellular debris was removed by centrifugation at 13,000 × g for 5 min at 4°C, and the protein was quantified by the bicinchoninic acid method using BSA dilutions as standard. Akt or ERK1/2 phosphorylation was then determined by Western blot as described previously (Moreno et al., 2014), using a rabbit anti-phospho-Ser473 Akt antibody (1:2500; Signalway Antibody) for Akt phosphorylation or mouse anti-phospho-Akt and ERK1/2 antibodies (1:2500; Sigma) and rabbit anti-ERK1/2 antibody that recognizes both phosphorylated and nonphosphorylated ERK1/2 (1: 40,000; Sigma).

β-Arrestin 2 recruitment. Arrestin recruitment was determined as described previously (Moreno et al., 2014). Briefly, BRET experiments were performed in HEK-293T cells 48 h after transfection with the cDNA corresponding to the indicated receptors fused or not to the YFP and β-arrestin 2–RLuc cDNA (0.5 μg). Cells (20 μg protein) were distributed in 96-well microplates (Corning 3600, white plates with white bottom; Sigma) and were incubated with the indicated antagonist for 10 min and stimulated with the agonist for 10 min before the addition of coelenterazine H (5 μM; Invitrogen). After 1 min of adding coelenterazine H, BRET between β-arrestin 2–RLuc and receptor YFP was determined and quantified as described above.

cAMP production. Transfected HEK-293T cells were incubated in serum-free medium for 16 h before the experiment. Cells were preincubated for 15 min at 37°C. The rate of this wavelength shift (in picometers) is directly proportional to the amount of DMR. Briefly, 24 h before the assay, the cells were seeded at a density of 5000 cells per well in 384-well microplates with 30 μl of growth medium and cultured for 24 h (37°C, 5% CO2) to obtain 70–80% confluent monolayers. Cells were washed twice with assay buffer (HBSS with 20 mM HEPES, pH 7.15) and incubated 2 h in 40 μl/well assay buffer with 0.1% DMSO at 24°C, the sensor plate was scanned, and a baseline optical signature was recorded before incubating the indicated antagonists for 30 min and adding 10 μl of agonist dissolved in assay buffer containing 0.1% DMSO. DMR responses were monitored for at least 8000 s. Kinetic results were analyzed using EnSpire Workstation Software version 4.10 (En- Spire Software), and curves were normalized with respect to the baseline.

In vivo VTA dendritic dopamine release. Male Sprague Dawley rats (3 months old; Charles River Laboratories) were used. Animals were housed two per cage and kept on a 12 h light/dark cycle with food and water available ad libitum. Experiments were performed during the light cycle. All animals used in the study were maintained in accordance with the guidelines of National Institutes of Health animal care, and the animal research conducted to perform this study was reviewed and approved by the National Institute on Drug Abuse Intramural Research Program Animal Care and Use Committee (Protocol 12-BNRRB-73). Rats were deeply anesthetized with 3 ml/kg Equithesin [4.44 g of chloral hydrate, 0.972 g of Na pentobarbital, 2.124 g of MgSO4, 44.4 ml of propylene glycol, 12 ml of ethanol, and distilled H2O up to 100 ml of final solution (National Institute on Drug Abuse Pharmacy)] and implanted unilaterally in the VTA (coordinates in mm from bregma with a 10° angle in the coronal plane: anterior, 5.6; lateral, 2.4; vertical, 9) with a specially designed microdialysis probe that allows the direct infusion of large peptides within the sampling area. After surgery, rats were allowed to recover in hemispherical CMA-120 cages (CMA Microdialysis) equipped with two-channel overhead fluid swivels (Instech) connected to a sample collector (CMA 470; CMA). Twenty-four hours after implanting the probe, in the middle of the light period of the light/dark cycle, experiments were performed on freely moving rats in the same hemispherical home cages in which they recovered overnight from surgery. An ACSF (in mM: 144 NaCl, 4.8 KCl, 1.7 CaCl2, and 1.2 MgCl2) was pumped through the probe at a constant rate of 1 μl/min. After a washout period of 90 min, dialysate samples were collected at 20 min intervals. For peptide infusion, orexins and CRF were dissolved in ACSF to a final concentration of 10 μM, whereas HIV TAT-fused peptides were dissolved in 0.1% DMSO in ACSF to a final concentration of 30 μM (TM1 and TM5) or 60 μM (TM7). All peptides were injected with a 1 μl syringe (Hamilton) driven by an infusion pump and coupled with silica tubing (73 μm inner diameter; Polymicro) to the microdialysis probe infusion port (dead volume, 40 nl), which was primed with ACSF and plugged during implantation. All peptides were delivered at a rate of 16.6 nl/min. The OX1R agonist SB334667 was dissolved in sterile saline and administered intraperitoneally (10 mg/kg) 40 min before peptide infusion. The CRF1R agonist NB127914 was dissolved in 5% DMSO in water and administered intraperitoneally (10 mg/kg) 40 min before peptide infusion. The σ2R agonist PRE-084 was dissolved in ACSF at a concentration of 100 μM and was perfused through the microdialysis probe (reverse dialysis). Cocaine HCl was administered intraperitoneally 24 h before the start of the microdialysis experiment at a dose of 15 mg/kg. At the end of the experiment, rats were given an overdose of Equithesin, the brains were extracted and fixed in formaldehyde, and probe placement was verified using cresyl violet staining. Dopamine content was measured by HPLC coupled with a coulometric detector (5200a Coulochrome III; ESA).

Statistics. Sample sizes were between 5 and 10, which our previous published work indicated are sufficient to perform appropriate statistical analysis. Parametric statistics (unpaired t test and one-way or repeated-measures ANOVA) were used, because the different groups analyzed showed normality and homogeneity of variance. GraphPad Prism software version 5 was used for the statistical analysis.

Results

Expression and functional characterization of heteromers between OX, R and CRF, R in transfected cells

BRET and PLA experiments were performed in HEK-293T cells transfected with OX, R–RLuc and CRF, R–YFP (Figs. 1A,B),

Navarro et al. • Orexin–CRF Receptor Heteromers in the VTA

J. Neurosci., April 29, 2015 • 35(17):6639–6653

6642 • J. Neurosci.
These fusion proteins properly trafficked to the cell membrane, as shown by confocal microscopy (Fig. 1C), and were functional, as shown by comparing their ability to increase ERK1/2 phosphorylation with that of native receptors (Fig. 1D). BRET saturation curves were obtained in cells expressing OX1R–RLuc and increasing amounts of CRF1R–YFP (Fig. 1A), with BRETmax of 186 ± 6 mBU and BRET50 of 54 ± 7, indicating that these receptors can indeed form heteromers. As a negative control, a low and linear BRET was detected in cells expressing CRF1R–RLuc and increasing amounts of GHSR1a–YFP (Fig. 1A). Accordingly, receptor heteromers were also visualized as red spots by using PLA in cells expressing OX1R–RLuc and CRF1R–YFP but not in cells expressing CRF1R–RLuc and GHSR1a–YFP (Fig. 1B).

CRF or the OX1R agonist orexin-A induced ERK1/2 phosphorylation in cells coexpressing CRF1R and OX1R (Fig. 2A–C). Orexin-A-induced signaling was inhibited by the OX1R antagonist SB334667 (SB; 1 μM), or the CRF1R antagonist NBI27914 (NBI; 1 μM), followed by treatment (7 min) with medium, CRF (100 nM), orexin-A (50 nM), or both. Values are means ± SEMs of five to six experiments per group and are expressed as percentage of basal levels (100%; dotted line). D. Akt phosphorylation was determined in cells transfected with CRF1R–YFP cDNA (0.3 μg; grey bar) or OX1R–RLuc cDNA (0.4 μg), followed by treatment with medium, CRF (100 nM), orexin-A (50 nM), or both. Values are means ± SEMs of five to six experiments per treatment and expressed as percentage of basal levels (100%; dotted line). E, F. β-arrestin 2 recruitment measured by BRET in cells transfected with CRF1R–YFP cDNA (0.3 μg; white bar) or OX1R–YFP cDNA (0.4 μg; black bar), or both (F) and β-arrestin 2–RLuc cDNA (0.5 μg). Cells were pretreated (10 min) with medium, CRF (100 nM), orexin-A (50 nM), or both. Values are means ± SEMs of five to six experiments per treatment. G, H. cAMP accumulation was determined in cells transfected with CRF1R–YFP cDNA (0.3 μg; grey bar) or OX1R–YFP cDNA (0.4 μg; black bar), or both (H). Cells were pretreated (10 min) with vehicle, the OX1R antagonist SB334667 (SB; 1 μM), or the CRF1R antagonist NBI27914 (NBI; 1 μM), followed by treatment (7 min) with medium, CRF (100 nM), orexin-A (50 nM), or both. Values are means ± SEMs of six to eight experiments per treatment and expressed as increases of basal levels or as decreases of forskolin-induced cAMP accumulation (for orexin-A; 100%; dotted line). In A, B, D–F, and H, One-way ANOVA followed by Bonferroni’s multiple comparison post hoc test shows significant single agonist effect versus basal values (*p < 0.05, **p < 0.01, and ***p < 0.001), or CRF plus orexin-A treatment versus CRF or orexin-A treatment (#p < 0.05) or antagonist plus agonist versus agonist with or without forskolin (&&p < 0.01, and &&&p < 0.001). In G, unpaired Student’s t test (two-tailed) shows significant difference of single agonist treatment versus basal values (***p < 0.001).
nist SB334867 and the CRF₁R antagonist NBI27914, that did not modify basal levels by themselves, and vice versa, CRF-induced ERK1/2 phosphorylation was antagonized by both NBI27914 and SB334667. Thus, CRF, R–OX₁R heteromers display cross-antagonism, a property seen in previous receptor heteromers (Guitart et al., 2014; Moreno et al., 2014). A negative crosstalk was also observed because ERK1/2 phosphorylation during coactivation of both receptors was significantly lower compared with that induced by single activation of either CRF/R or OX₁R (Fig. 2A). Cross-antagonism and negative crosstalk were not attributable to either the lack of ligand specificity, because they were not observed in cells expressing single receptors (Fig. 2B), or a change in the shape of the time–response curve of ERK1/2 phosphorylation (Fig. 2C). Negative crosstalk and cross-antagonism were also observed at the level of Akt phosphorylation (Fig. 2D). β-Arrestin recruitment was also analyzed, because it has been shown to mediate ERK1/2 and Akt phosphorylation for several GPCRs (Kovacs et al., 2009). Orexin-A but not CRF significantly increased control BRET values in cells expressing β-arrestin 2–RLuc and OX₁R–YFP. Similarly, CRF but not orexin-A increased BRET values in cells expressing β-arrestin 2–RLuc and CRF₁R–YFP (Fig. 2E), indicating both the specificity of the ligands and the ability of these receptors to recruit β-arrestin 2 when activated. Significantly, not only CRF but also orexin-A significantly increased BRET values in cells expressing β-arrestin 2–RLuc, CRF₁R–YFP, and OX₁R (Fig. 2F). During coactivation with both agonists CRF and orexin-A, a negative crosstalk was observed at the level of β-arrestin 2 recruitment. Furthermore, cross-antagonism could also be demonstrated, and CRF-promoted and orexin-A-promoted β-arrestin 2 recruitment were counteracted by SB334867 and NBI27914, respectively (Fig. 2F).

Orexin-A decreased forskolin-stimulated cAMP in cells expressing OX₁R, indicating receptor coupling to a Gₛ protein, and CRF promoted an increase in cAMP production in cells expressing CRF₁R, indicating receptor coupling to a Gₛ protein (Fig. 2G). The same findings were observed in cells coexpressing OX₁R and CRF₁R, suggesting that the receptors can signal independently through their preferred G-proteins in the CRF₁R–OX₁R heteromer (Fig. 2H). Cross-antagonism could also be observed at the adenylcyclase level in cells coexpressing OX₁R and CRF₁R. Thus, orexin-A-induced inhibition of forskolin-stimulated cAMP accumulation was counteracted not only by the OX₁R antagonist SB334867 but also by the CRF₁R antagonist NBI27914. Equally, CRF-induced cAMP accumulation was counteracted by both NBI27914 and SB334867 (Fig. 2H). A canonical Gₛ–Gᵢ interaction at the adenylcyclase level could not be observed during coactivation of both receptors with CRF and orexin-A, showing cAMP accumulation similar to that obtained with CRF alone (Fig. 2H). This would indicate a negative crosstalk by which CRF₁R activation counteracts OX₁R signaling through Gᵢ in the CRF₁R–OX₁R heteromer. These findings were supported with experiments using label-free DMR technology, which allows measuring G-protein-mediated signaling in living cells. Agonist-induced time–response curves in the absence or presence of pertussis toxin (PTX) or cholera toxin (CTX) were obtained in cells expressing both OX₁R and CRF₁R (Fig. 3A). The maximum response in-

![Figure 2](image-url)
produced by orexin-A or CRF (derived from time–response curves) was significantly inhibited with pretreatment with either PTX or CTX (Fig. 3D). Conversely, in cells only expressing CRF1R, the effect of CRF was inhibited by CTX but not with PTX (Fig. 3B), whereas in cells only expressing OX1R, the effect of orexin-A was only inhibited by PTX (Fig. 3C). These results demonstrate that the heteromer can interact simultaneously with both Gαi- and Gαs-proteins. Negative crosstalk and cross-antagonism were also observed by DMR. The effect (maximum response) of CRF or orexin-A was inhibited by both NBI27914 and SB334867, and the coactivation with CRF and orexin-A produced a lower response than the one obtained by single activation (Fig. 3E). These results suggest strongly that negative crosstalk and cross-antagonism observed for G-protein-dependent and β-arrestin-dependent signaling pathways constitute biochemical characteristics of CRF1R–OX1R heteromers.

BiFC experiments (Fig. 4A) were performed to check the ability of peptides with the amino acid sequence of OX1R TM domains to destabilize CRF1R–OX1R heteromer, as described recently for the dopamine D1–D3 receptor heteromer (Guitart et al., 2014). HIV TAT peptides fused to OX1R TM1, TM5, and TM7 peptides were used. Significant fluorescence could be detected in HEK-293T cells transfected with CRF1R fused to the N-terminal fragment of YFP Venus (nVenus) and OX1R fused to the C-terminal fragment YFP Venus (cVenus) as a result of YFP Venus reconstitution by CRF1R–OX1R heteromerization. Treatment with OX1R TM1 and TM5 peptides alone or in combination, but not TM7, inhibited YFP Venus reconstitution, and the effect of TM1 plus TM5 was more pronounced than the effect obtained by either peptide alone (Fig. 4B). ERK1/2 phosphorylation crosstalk and cross-antagonism experiments were then performed in cells pretreated with OX1R TM1 (Fig. 4C) or TM5 (Fig. 4D) peptides. Both peptides counteracted the negative crosstalk and cross-antagonism (Fig. 4C, D). Importantly, TM7 peptide, which was not able to alter the structure of CRF1R–OX1R in BiFC experiments, was also ineffective at counteracting the negative crosstalk and cross-antagonism (Fig. 4E). None of the peptides themselves significantly changed signaling from each of the receptors when activated alone with their respective agonists (Fig. 4C–E). These results demonstrate that the negative crosstalk and cross-antagonism depend on the integrity of the quaternary structure of the CRF1R–OX1R heteromer and, therefore, that constitute biochemical characteristics of the heteromer.
Two CRF₁R functional mutants were used to provide some insight about the conformational changes involved in the negative crosstalk between ligands binding to the CRF₁R–OX₁R heteromer: (1) a truncated mutant (CRF₁R₄₃₃) that lacks a large part of the N-terminal domain and is not able to bind CRF but can still be activated by a small peptide that corresponds to the N-terminal part of CRF (peptide 1₄b, which binds to the juxtamembrane activating domain of CRF₁R; Devigny et al., 2011); and (2) a receptor that contains a mutation in the third intracellular loop and has enhanced constitutive activity (CRF₁R₄₃₂). Both mutants were able to form heteromers with OX₁R as detected by BRET experiments without significant differences in BRETₘₐₓ and BRET₅₀ with respect to the CRF₁R (Fig. 5A, B). As expected, CRF or orexin-A did not induce ERK₁/2 phosphorylation in HEK-293T cells expressing CRF₁R₄₃₃ alone (Fig. 5C). Orexin-A, but not CRF, was able to signal in cells expressing CRF₁R₄₃₃–OX₁R heteromers, but orexin-A-induced signaling was not modified by CRF or the CRF₁R antagonist NBI27914 (Fig. 5D, E). Nevertheless, in these cells, peptide 1₄b promoted ERK₁/2 phosphorylation, and a negative crosstalk was observed between orexin-A and peptide 1₄b (Fig. 5F). These results indicate that an active conformation of the CRF₁R is involved with the negative crosstalk of receptor agonists in the CRF₁R–OX₁R heteromer. This was further corroborated using the CRF₁R₄₃₂ mutant, which displays high constitutive activity. Single expression of CRF₁R₄₃₂ showed increased basal ERK₁/2 phosphorylation (compared with nontransfected cells), which could not be increased further by CRF (Fig. 5G). The same findings were also obtained in cells expressing CRF₁R₄₃₂ and OX₁R (Fig. 5H). In addition, orexin-A did not increase MAPK signaling, in agreement with the active conformation of CRF₁R facilitating an allosteric inhibition of the orexin-A signaling (Fig. 5H).

CRF₁R–OX₁R heteromers in the VTA control dendritic dopamine release

In rat VTA slices, orexin-A and CRF promoted ERK₁/2 phosphorylation (Fig. 6A), coactivation with orexin-A and CRF showed negative crosstalk, and both the CRF₁R antagonist NBI27914 and the OX₁R antagonist SB334667, which do not modify basal levels by themselves, antagonized the effect of orexin-A and CRF, thus showing cross-antagonism (Fig. 6A). Crosstalk and cross-antagonism disap-

Figure 5. Involvement of the active conformation of CRF₁R with the negative crosstalk of receptor agonists in the CRF₁R–OX₁R heteromer. A, B, BRET saturation experiments in HEK-293T cells transfected with OX₁R–RLuc cDNA (0.2 μg) and increasing cDNA amounts (0.05–0.5 μg) of CRF₁R–YFP (circles), CRF₁R₄₃₃ mutant (triangles in A), or CRF₁R₄₃₂ mutant (triangles in B). BRET is expressed as mBU as a function of 1000 × the ratio between fluorescence of the acceptor (YFP) and Luciferase activity of the donor (RLuc). Values are means ± SEs of five to six replications of one independent experiment per point. C–F, ERK₁/2 phosphorylation in HEK-293T cells transfected with CRF₁R₄₃₃ mutant cDNA (0.3 μg; B) alone or transfected with OX₁R cDNA (0.4 μg) pretreated (10 min) with vehicle, the OX₁R antagonist SB334667 (5B, 1 μM), or the CRF₁R antagonist NBI27914 (NB1, 1 μM), followed by treatment (7 min) with CRF (100 nM), orexin-A (50 nM) or both, or with peptide 1₄b (10 nM; C–E). Values are means ± SEs of five to six experiments per group expressed as percentage of basal (100%). One-way ANOVA followed by Bonferroni’s multiple comparison post hoc test shows significant differences of single agonist treatment versus basal values (**p < 0.01 and ***p < 0.001), CRF plus orexin-A treatment versus CRF or orexin-A treatment (*p < 0.05) or orexin-A plus SB334667 or peptide 1₄b versus orexin-A alone (***p < 0.05 and 4444p < 0.001). G, H, ERK₁/2 phosphorylation in HEK-293T cells transfected with CRF₁R₄₃₂ mutant cDNA (0.3 μg; F) alone or transfected with OX₁R (0.4 μg) treated (7 min) with vehicle or with CRF (100 nM), orexin-A (50 nM) or both (G). Values are means ± SEs of five to six experiments per group expressed as percentage of basal values obtained in nontransfected cells (100%).
Expression and function of CRF1R–OX1R heteromers in the VTA. A, B, ERK1/2 phosphorylation in rat VTA slices preincubated (1 h) with vehicle (A) or HIV Tat–fused peptides with the amino acid sequences of OX1R TM1 and TM5 (10 μM) or TM7 (20 μM) (30 min) with or without the OX1R antagonist SB334667 (SB; 10 μM) or the CRF1R antagonist NBI27914 (NBI; 10 μM), or both, followed by incubation (10 min) with vehicle, CRF1R (1 μM), OX1R (1 μM), or both (B). Values are means ± SEMs of five to six experiments per group expressed as percentage of basal values (100%). One-way ANOVA followed by Bonferroni’s multiple comparison post hoc test shows significant differences of agonist treatment versus basal values (*p < 0.05, **p < 0.01, and ***p < 0.001), CRF plus orexin-A treatment versus CRF or orexin-A treatment (†p < 0.05), or agonist plus antagonist treatment versus agonist alone (‡p < 0.05 and §§p < 0.01). C, Representative coronal section of a rat brain (5.6 mm posterior from bregma), stained with cresyl violet, showing the track left by the tip of the modified microdialysis probe in the VTA (arrow). D, E, Dopamine (DA) levels in dialysates sampled from the VTA after slow infusion (1 μl/h) of orexin-A (1 μl, 10 μM), orexin B (1 μl, 10 μM), and/or CRF (1 μl, 10 μM) after previous systemic (intraperitoneal) administration of vehicle, SB334667 (SB; 10 mg/kg; D), or NBI27914 (NBI; 10 mg/kg; E) or with preinfusion and coinfusion (1 μl/h) of OX1R TM1 plus TM5 (30 μM) or TM7 (60 μM) (F). Values are means ± SEMs of 7–10 experiments per group and are expressed as percentage of basal values (average of first 3 values before orexin-A or CRF infusion). A repeated measures ANOVA followed by Bonferroni’s multiple comparison post hoc test showed significant differences (filled symbols, p < 0.05) versus the last basal values before orexin-A or CRF infusion. The same data on the effect of infusion of orexin-A alone are shown in D–F for comparison.

Figure 6. Expression and function of CRF1R–OX1R heteromers in the VTA. A, B, ERK1/2 phosphorylation in rat VTA slices preincubated (1 h) with vehicle (A) or HIV Tat–fused peptides with the amino acid sequences of OX1R TM1 and TM5 (10 μM) or TM7 (20 μM) (30 min) with or without the OX1R antagonist SB334667 (SB; 10 μM) or the CRF1R antagonist NBI27914 (NBI; 10 μM), or both, followed by incubation (10 min) with vehicle, CRF1R (1 μM), orexin-A (1 μM), or both (B). Values are means ± SEMs of five to six experiments per group expressed as percentage of basal values (100%). One-way ANOVA followed by Bonferroni’s multiple comparison post hoc test shows significant differences of agonist treatment versus basal values (*p < 0.05, **p < 0.01, and ***p < 0.001), CRF plus orexin-A treatment versus CRF or orexin-A treatment (†p < 0.05), or agonist plus antagonist treatment versus agonist alone (‡p < 0.05 and §§p < 0.01). C, Representative coronal section of a rat brain (5.6 mm posterior from bregma), stained with cresyl violet, showing the track left by the tip of the modified microdialysis probe in the VTA (arrow). D, E, Dopamine (DA) levels in dialysates sampled from the VTA after slow infusion (1 μl/h) of orexin-A (1 μl, 10 μM), orexin B (1 μl, 10 μM), and/or CRF (1 μl, 10 μM) after previous systemic (intraperitoneal) administration of vehicle, SB334667 (SB; 10 mg/kg; D), or NBI27914 (NBI; 10 mg/kg; E) or with preinfusion and coinfusion (1 μl/h) of OX1R TM1 plus TM5 (30 μM) or TM7 (60 μM) (F). Values are means ± SEMs of 7–10 experiments per group and are expressed as percentage of basal values (average of first 3 values before orexin-A or CRF infusion). A repeated measures ANOVA followed by Bonferroni’s multiple comparison post hoc test showed significant differences (filled symbols, p < 0.05) versus the last basal values before orexin-A or CRF infusion. The same data on the effect of infusion of orexin-A alone are shown in D–F for comparison.

Peared when VTA slices were treated with the CRF1R–OX1R destabilizing peptides OX1R TM1 plus TM5 (10 μM; Fig. 6B), whereas the negative control TM7 peptide (at the same total peptide concentration, 20 μM) was ineffective (Fig. 6B), which demonstrates the presence of CRF1R–OX1R heteromers in the VTA.

To investigate the functional role of CRF1R–OX1R heteromers in the VTA, we analyzed dopamine release in the VTA using in vivo microdialysis experiments (Fig. 6C–F). Dendritic dopamine release by mesencephalic dopaminergic cells resembles that of the terminal regions, possessing a similar uptake mechanism and a finite releasable storage pool (Kita et al., 2009). Furthermore, local dopamine release in the VTA is a correlate of dopaminergic cell firing (Legault and Wise, 1999). Initial attempts to perfuse orexin-A through the dialysis probe (reverse dialysis) were unsuccessful, which included testing of different compositions of ACSF and different dialysis membranes of different materials and different cutoff, as analyzed with mass-spectrometry analysis of in vitro-recovered dialysates (data not shown). A specialized probe with an embedded silica infusion port was designed (Fig. 7) that allowed simultaneous constant slow delivery (1 μl/h) of large peptides (ligands and OX1R TM peptides) in the same brain region where the microdialysis probe is sampling the extracellular concentration of dopamine. VTA infusion of orexin-A (10 μM) for 60 min produced dopamine release, which remained elevated >1 h after withdrawal (Fig. 6D). The average basal dialysate concentration of dopamine of a total of 121 animals was 2.37 ± 0.15 nM (mean ± SEM). This effect was attributable to selective activation of OX1R, because it was not reproduced by a 10 μM infusion of the selective OX1R agonist orexin-B (Sakurai et al., 1998; de Lecea et al., 1998) and was counteracted by the previous systemic administration of an effective dose (10 mg/kg, i.p.) of the selective OX1R receptor antagonist SB334867 (Richards et al., 2008; Fig. 6D). The infusion of CRF (10 μM) or the systemic administration of an effective dose (10 mg/kg, i.p.) of the CRF1R antagonist NBI27914 did not produce any significant change in the extracellular concentration of dopamine, but both counteracted the effect of orexin-A (Fig. 6E), demonstrating the negative crosstalk and cross-antagonism. These results strongly suggest that dendritic VTA dopamine release is under the control of CRF1R–OX1R heteromers. This was further demonstrated using CRF1R–OX1R destabilizing peptides. Infusion of OX1R TM1 (30 μM) plus TM5 (30 μM) peptides but not the control TM7 peptide (at the same total peptide concentration, 60 μM) counteracted the orexin-A–CRF negative crosstalk (Fig. 6F). The effect of the TM peptides was not long lasting, probably because of a faster clearance compared with that of the larger and more hydrophilic orexin-A and CRF molecules. These results demonstrate that CRF1R–OX1R heteromers modulate VTA dopamine release.

CRF1R–OX1R heteromers are signaling units that can be modulated by cocaine in transfected cells and the VTA

In cells expressing CRF1R and OX1R, pretreatment for 2 h with 30 μM cocaine completely disrupted the negative crosstalk and...
cross-antagonism between CRF₁R and OX₁R ligands on MAPK signaling (Fig. 8A, black, bars) and β-arrestin 2 recruitment (Fig. 8B, black bars) that was seen in the absence of cocaine (Fig. 8A, B, white bars). Thus, cocaine blocks the allosteric intermolecular interactions in the CRF₁R–OX₁R heteromers that conduce the crosstalk and cross-antagonism between CRF₁R and OX₁R ligands.

We next explored the effect of cocaine in the rat VTA. The extracellular level of cocaine in the rat brain reached after pharmacologically significant doses is estimated to be 15 μM (Pettit et al., 1990). A higher cocaine concentration (100 μM) was then used to allow diffusion into the VTA slices. Cocaine pretreatment for 4 h counteracted the negative crosstalk of orexin-A and CRF on ERK1/2 phosphorylation. Furthermore, cross-antagonism of SB334867 or NBI27914 on ERK1/2 phosphorylation induced by CRF or orexin-A was not observed (Fig. 8C). Therefore, cocaine also disrupts the allosteric interactions within the CRF₁R–ORX₁R heteromer in the VTA.

σ₁Rs mediate the disruptive effects of cocaine on CRF₁R–ORX₁R heteromer function

It has been found recently that cocaine can disrupt allosteric interactions between ligands in dopamine D₁–histamine H₃ receptor (H₃,R) heteromers by acting on σ₁Rs that oligomerize with the heteromer (Moreno et al., 2014). We explored whether this mechanism could be involved in the disruptive effects of cocaine on CRF₁R–ORX₁R heteromer function. A saturable BRET curve was obtained in HEK-293T cells expressing CRF₁R–RLuc and increasing concentrations of σ₁R–YFP (Fig. 9A), indicating a direct interaction between σ₁R and CRF₁R. Cocaine produced a significant change in BRETₘᵢₓ and BRET₅₀ BRET values (Fig. 9A), indicating a cocaine-induced change in the quaternary structure of the σ₁R–CRF₁R oligomers. Conversely, no significant BRET was detected in cells expressing OX₁R–RLuc and σ₁R–YFP in the absence or presence of cocaine (Fig. 9B). These results suggest that σ₁R can interact with CRF₁R–ORX₁R heteromers by binding to CRF₁R in the heteromer. The heterotrimeric complex expression was demonstrated with SRET (Fig. 10A; Carriba et al., 2008). In HEK-293T cells expressing a constant amount of OX₁R–RLuc and σ₁R–YFP and increasing amounts of CRF₁R–Cherry, a net SRET saturation curve was obtained (Fig. 10B) with an SRETₘᵢₓ of 0.31 ± 0.01 mSU and an SRET₅₀ of 0.08 ± 0.01. These results provide evidence for the existence of σ₁R–CRF₁R–OX₁R oligomers. Cocaine produced a significant change in SRETₘᵢₓ and SRET₅₀ values (SRETₘᵢₓ of 0.19 ± 0.03 mSU and a SRET₅₀ of 0.056 ± 0.002), indicating a cocaine-induced change in the quaternary structure of the σ₁R–CRF₁R–OX₁R oligomers. The involvement of σ₁R in the effects of cocaine on CRF₁R–OX₁R heteromers function in the VTA was demonstrated by using selective σ₁R ligands. In VTA slices, pretreatment for 4 h with the σ₁R agonist PRE-084 (Garcés-Ramírez et al., 2011) counteracted the negative crosstalk on ERK1/2 phosphorylation detected during CRF and orexin-A coadministration (Fig. 10C). Moreover, pretreatment with the σ₁R antagonist PD144418 (Akunne et al., 1997) blocked the effect of cocaine, and the negative cross-
presence of PRE-084, orexin-A was more effective, particularly during the first two samples (40 min) after its infusion. Interestingly, CRF, which was ineffective by itself, also produced a prolonged significant elevation of extracellular dopamine during perfusion with the σ₁R agonist (Fig. 10F). These results match with the in vitro experiments and indicate the existence of a negative crosstalk between orexin-A and CRF, which is counteracted by σ₁R activation. These striking results are in total agreement with σ₁R–CRF, R–OX₁R oligomers modulating VTA dopamine release.

We then studied whether one single administration of cocaine (15 mg/kg) could also reproduce the effects of the acute perfusion of the σ₁R agonist PRE-084 attributable to a long-term disruption of the allosteric interactions in the CRF, R–OX₁R heteromer, as demonstrated recently for σ₁R–D₁R–H₃R oligomers (Moreno et al., 2014). In fact, a significant elevation in the extracellular concentration of VTA dopamine was observed after infusion of CRF or confusion of orexin-A and CRF (Fig. 10G).

Discussion

Class B GPCR CRF₁R has been shown previously to homomerize (Milan-Lobo et al., 2009) and also heteromerize with the class A GPCRs for vasopressin and its non-mammalian vertebrate homolog vasotocin in transfected cells (Mikhailova et al., 2007; Murat et al., 2012). Similarly, evidence has been reported for OX₁R homomerization and heteromerization in artificial cell systems (Ellis et al., 2006; Jännti et al., 2014). However, although colocalized in the VTA, CRF, R–OX₁R heteromerization has not been described, and, in fact, it has been argued that independent actions of CRF and orexin-A in the VTA are involved in reinstatement of cocaine seeking (Wang et al., 2009). In the present study, we demonstrate the existence of functional CRF₁R–OX₁R heteromers in transfected cells and the VTA, in which they exert a significant functional control of dopaminergic cells. By means of allosteric interactions within the CRF₁R–OX₁R heteromer, CRF and orexin-A antagonize each other’s ability to signal and promote VTA dendritic dopamine release, indicating that this heteromer should play a significant role under stress conditions, during concomitant CRF and orexin-A VTA release. Additional important findings were the evidence for oligomerization of σ₁R with the CRF₁R–OX₁R heteromer and the ability of σ₁R agonists, including cocaine, to modify the quaternary structure of the heteromer to block the functional allosteric interactions between orexin-A and CRF within the heteromer.

Molecular interactions between CRF₁R, R and OX₁R were demonstrated in HEK-293T cells by using different approaches, talk between CRF and orexin-A was still present with preincubation of cocaine and PD144418 (Fig. 10D).

Cocaine exerts its stimulant effects predominantly by its ability to block the dopamine transporter (DAT; Kita et al., 2009). To dissect the σ₁R effects in microdialysis experiments, we used the selective σ₁R agonist PRE-084, which reproduced the effects of cocaine in the in vitro experiments and has very low affinity for the VTA (Garce´s-Ramírez et al., 2011). Direct perfusion of the σ₁R agonist PRE-084 (100 μM) through the microdialysis probe did not modify the extracellular concentration of dopamine (Fig. 10F) but counteracted the negative crosstalk between orexin-A and CRF. Thus, in the presence of PRE-084, orexin-A plus CRF produced an increase in extracellular dopamine that was larger than the one induced by orexin-A alone (Fig. 10E). In fact, in the...
which included BRET, fluorescence complementation, and PLA, but also additional demonstration came from results of signaling experiments indicating the expression of CRF, R–OX1R heteromers at the membrane level. To our knowledge, the ability of an antagonist of one receptor to block the agonist-mediated signaling of another receptor has only been reported in the frame of receptor heteromerization (Ferre´ et al., 2014). Also, the ability of orexin-A to induce an interaction between β-arrestin 2–RLuc and CRF, R–YFP indicates recruitment of β-arrestin 2 to the CRF, R–OX1R heteromer. Moreover, the surprising ability of PTX to counteract Gs-mediated CRF1R signaling and that of CTX experiments in transfected cells demonstrated that specific OX1R TM peptides versus σ1R agonists observed in vivo, with a respective transient versus long-lasting (apparently irreversible) destabilization of CRF, R–OX1R heteromer function, should be related to the different molecular mechanisms and different modifications of the quaternary structure of the heteromer involved. Particularly significant will be the elucidation of the apparently irreversible effect of σ1R agonists, such as cocaine.

An important amount of experimental data demonstrates the involvement of σ1R in many pharmacologic, including rewarding, effects of cocaine (Maurice and Su, 2009; Robson et al., 2012). Recent studies describe a role of oligomerization of σ1R with D1R or D2R in the acute psychostimulants effects of cocaine (Navarro et al., 2010, 2013) and with voltage-gated Kv1.2 potassium channels in long-lasting behavioral responses (Kourrich et al., 2013). Also, oligomerization of σ1R, D1R, and H1Rs (σ1R–D1R–H1R heteromers) has been involved in the neurotoxic effects of cocaine (Moreno et al., 2014). Interestingly, when comparing the effects of cocaine binding with either σ1R, D1R–H1R or σ1R–CRF1R–OX1R oligomers, a common mechanism emerges, the loss of the allosteric interactions between ligands in the heteromer.

The present results strongly suggest that CRF, R–OX1R heteromers localized in the VTA convey the previously established significant control of dopaminergic cell function by CRF and orexin-A in cocaine-treated animals. The counteraction of the negative crosstalk between orexin-A and CRF in the VTA by the simultaneous application of the σ1R agonist PRE-084 or by the previous administration of cocaine provides a mechanism by which CRF can only induce VTA dendritic dopamine release in animals exposed previously to cocaine (Wang et al., 2005). Under these conditions, CRF, R-mediated signaling is not inhibited by a tonic activation of OX1R by endogenous orexin-A. Counteraction of the allosteric interactions between agonists in the CRF, R–OX1R heteromer can also explain the apparent CRF-independent ability of orexin-A to release dopamine in the VTA and to induce cocaine seeking (Wang et al., 2009). Remarkably, in the present study, cocaine produced a modification of CRF, R–OX1R heteromeric function that was observed 24 h after one single systemic administration. Very similar findings were reported recently for σ1R–D1R–H1R oligomers, in which the ability of H3R ligands to modulate D1R-mediated signaling was also disrupted 24 h after one single systemic administration of cocaine (Moreno et al., 2014). Therefore, one single administration could explain some effects of cocaine attributed previously to its repeated administration.

Of the many new questions this study raises is the identification of the precise localization of CRF, R–OX1R heteromers in the VTA. Both receptors are potentially colocalized in dopaminergic cells and their glutamatergic afferents Borgland et al., 2010), in which CRF, R–OX1R heteromers could directly or indirectly control the extracellular levels of dopamine in the VTA. Second, our data indicate that, under basal conditions, the effects of CRF and orexin-A in the VTA are interdependent and mediated by CRF, R–OX1R heteromers, but they also suggest that endogenous σ1R ligands should be able to act as cocaine and therefore promote independent effects of CRF and orexin-A. Those ligands and the conditions under which they are produced in the VTA...
still need to be determined. Third is to understand the potential changes in \( \sigma_1 \)-R–CRF1R–OX1R oligomers in acute versus long-term exposure to cocaine. It has been shown that repeated cocaine exposure increases the levels of \( \sigma_1 \)-R in the brain (Robson et al., 2012), and cocaine-mediated upregulation of striatal \( \sigma_1 \)-R has been reported to increase the presence of \( \sigma_1 \)-Kv1.2 oligomers at the plasma membrane, which has been suggested to be involved in sensitization to its psychostimulant effects (Kourrich et al., 2013). Therefore, upregulation of \( \sigma_1 \)-R in the VTA could increase the proportion of \( \sigma_1 \)-R–CRF1R–OX1R oligomers, leading to more profound cocaine-induced changes in the control of VTA dendritic dopamine release by CRF and orexin-A. Those changes could explain the CRF, R-dependent augmented cocaine seeking in response to stress or CRF delivered into the VTA after long-access self-administration (Blacktop et al., 2011). Altogether, the present study demonstrates a significant functional and pharmacological role of \( \sigma_1 \)-R in the modulation of CRF, R–OX1R heteromers during physiological conditions and under conditions of acute cocaine administration and withdrawal. Addressing the study of \( \sigma_1 \)-R–CRF1R–OX1R oligomers in animal models of psychostimulant abuse should provide significant additional information that would support their role as new therapeutic targets.

References

CrossRef Medline

Figure 10. Involvement of \( \sigma_1 \)-R in the disruptive effect of cocaine on CRF, R–OX1R heteromer function. A, Scheme showing SRET (see Results). B, SRET saturation experiments in HEK-293T cells expressing a constant amount of \( \sigma_1 \)-R–RLuc cDNA (0.2 \( \mu \)g of cDNA transfected) and \( \sigma_1 \)-R–YFP cDNA (0.3 \( \mu \)g) and increasing amounts of CRF1R–Cherry cDNA (0.05–0.6 \( \mu \)g) in controls (black curve) or cocaine-treated (30 min, 30 \( \mu \)M; red curve) cells. SRET, expressed as mSU, is given as a function of the ratio between the fluorescence of the acceptor (Cherry) and the Luciferase activity of the donor (RLuc). Values are means ± SEs of seven to eight replications of one independent experiment per point. C, ERK1/2 phosphorylation in rat VTA slices preincubated (4 h) with \( \sigma_1 \)-R agonist PRE-084 (1 \( \mu \)M), followed by treatment (10 min) with CRF (1 \( \mu \)M), orexin-A (1 \( \mu \)M), or both. D, ERK1/2 phosphorylation in rat VTA slices preincubated (4 h) with \( \sigma_1 \)-R antagonist PD144418 (1 \( \mu \)M), with or without cocaine (100 \( \mu \)M), followed by treatment (10 min) with CRF (1 \( \mu \)M), orexin-A (1 \( \mu \)M), or both. In C and D, values are means ± SEs of five to six experiments per group expressed as percentage of basal values (100%). One-way ANOVA followed by Bonferroni’s multiple comparison post hoc test showed significant differences versus basal (* \( p < 0.05 \)) and CRF plus orexin-A treatment versus CRF or orexin-A treatment (## \( p < 0.05 \)). E–G, Dopamine (DA) levels in dialysates sampled from the VTA after slow infusion (1 \( \mu \)l/h) of orexin-A (1 \( \mu \)l, 10 \( \mu \)M) and/or CRF (1 \( \mu \)l, 10 \( \mu \)M) with preinfusion and coinfusion of the \( \sigma_1 \)-R agonist PRE-084 (PRE; 100 \( \mu \)M) or previous systemic (intraperitoneal) administration of cocaine (COC; 15 mg/kg; 24 h before the microdialysis experiment). Values are means ± SEs of 7–10 experiments per group and are expressed as percentage of basal values (average of first 3 values before orexin-A or CRF infusion). A repeated-measures ANOVA (including only the basal value before orexin-A or CRF infusion) followed by Bonferroni’s multiple comparison post hoc test showed significant differences (filled symbols, \( p < 0.05 \)) versus the last basal values before orexin-A or CRF infusion. Data on the effect of infusion of orexin-A alone in E are the same shown in Figure 6D–F.
Blacktop JM, Seubert C, Baker DA, Ferda N, Lee G, Graf EN, Maantsh JR (2011) Augmented cocaine seeking in response to stress or CRF delivered into the ventral tegmental area following long-access self-administration is mediated by CRF receptor type 1 but not CRF receptor type 2. J Neurosci 31:11396–11403. CrossRef Medline


